Ann: Close of Rights Issue, page-25

First 25 Last

Share
Profile

Follow
goedy

461 Posts.

96

23/03/24

12:23

Post #: 73024902
Share

Originally posted by smellyfingers: ↑

Well I don't take it personally that you don't pay much attention to me @josiejow :] but my math is pretty much straight forward and I would be interested to understand how you come to thinking that RHY is now flush with cash until end of December as you say it is ???

My math is this and I have adjusted this to be a little more generous than I previously posted.

Its all there in the RHY reports and reads like this.

Cash at 31 December 2023 = $1.2M
Add cash from Rights issue = $2.4M
Less cash burn for March quarter 2024 = ($1.5M)
Less liabilities at 31 December 2023 = ($0.7M)

THEREFORE Net cash at 31 March = $1.4M

As RHY shall have LESS than 2 quarters cash on hand at 31 March they will have to address this in Item 8.6 of their upcoming Appendix 4C.

This assumes that they do NOT receive their $1.2M ATO rebate for reclassifying the ColoSTAT stock to RUO by the end of next week. Just on this point I have spoken with my tax accountant here and she is of the view that the ATO may not look favorably on a retrospective reclassification by RHY and subsequent claim [LIKE IN REJECTING THE CLAIM].

Also RHY stated that they expected to get some additional funds back from overseas R&D spend. My advice here is that to be eligible to claim any overseas R&D spend RHY would have had to have received an "Advanced Ruling" from the ATO prior to the start of the FY23 [like before 1 July 2023]. Did they do this ?

Finally a stock broker friend of mine thinks that as Fidelity chose NOT to support the rights issue [as can be seen in there being no appearance on the Options top 20 that RHY has disclosed] it may create significant headwinds for them or PAC Partners gaining investor confidence to take up the shortfall shares they need to place to stay in business.

As I said I am happy to watch from the sidelines here.

Expand

Nice forensic work there on Fidelity. Holy Cow! You know things are finished when even Fidelity walked away from this one. They wouldnt have put a great deal of investigation into this purcahse, but even on face value there was no point.

RHY Price at posting: 9.3¢ Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 25 more messages in this thread...

First 25 Last

Add RHY (ASX) to my watchlist

(20min delay)
Last 6.0¢		Change -0.001(1.64%)		Mkt cap ! $14.91M

Open	High	Low	Value	Volume
6.1¢	6.2¢	6.0¢	$7.244K	119.2K

Buyers (Bids)

No.	Vol.	Price($)
1	54512	6.0¢

Sellers (Offers)

Price($)	Vol.	No.
6.2¢	144742	1

View Market Depth

No.	Vol.	Price($)
1	54512	0.060
3	26241	0.058
1	62500	0.056
1	54545	0.055
1	59995	0.050

Price($)	Vol.	No.
0.062	144742	1
0.063	34	1
0.065	9750	1
0.066	80000	1
0.070	75394	2

Last trade - 15.39pm 09/07/2024 (20 minute delay)

RHY (ASX) Chart

Ann: Close of Rights Issue, page-25

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Close of Rights Issue, page-25

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News